Journal of Neuroimmunology
Volume 239, Issue 1 , Pages 1-12 , 28 October 2011

Targeting Toll-like receptors: Emerging therapeutics for multiple sclerosis management

  • M. Gambuzza

      Affiliations

    • Department of Experimental Pathology and Microbiology, University of Messina, Messina, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 902213320; fax: + 39 902213312.
    • ,
  • N. Licata

      Affiliations

    • IRCCS Centro Neurolesi “Bonino-Pulejo”, Messina, Italy
    • ,
  • E. Palella

      Affiliations

    • IRCCS Centro Neurolesi “Bonino-Pulejo”, Messina, Italy
    • ,
  • D. Celi

      Affiliations

    • IRCCS Centro Neurolesi “Bonino-Pulejo”, Messina, Italy
    • ,
  • V. Foti Cuzzola

      Affiliations

    • IRCCS Centro Neurolesi “Bonino-Pulejo”, Messina, Italy
    • ,
  • D. Italiano

      Affiliations

    • IRCCS Centro Neurolesi “Bonino-Pulejo”, Messina, Italy
    • ,
  • S. Marino

      Affiliations

    • IRCCS Centro Neurolesi “Bonino-Pulejo”, Messina, Italy
    • ,
  • P. Bramanti

      Affiliations

    • IRCCS Centro Neurolesi “Bonino-Pulejo”, Messina, Italy

Received 15 March 2011 ,Revised 9 June 2011 ,Accepted 10 August 2011.

References 

  1. Akira S. Innate immunity to pathogens: diversity in receptors for microbial recognition. Immunol. Rev. 2009;227:5–8
  2. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801
  3. Andersson A, Covacu R, Sunnemark D, Danilov AI, Dal Bianco A, Khademi M, et al. Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J. Leukoc. Biol. 2008;84:1248–1255
  4. Andreakos E, Foxwell B, Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?. Immunol. Rev. 2004;202:250–265
  5. Arslan F, de Kielijn DP, Timmers L, Doevendands PA, Pasterkamp G. Bridging innate immunity and myocardial ischemia/reperfusion in injury: the search for therapeutic targets. Curr. Pharm. Des. 2008;14:1205–1216
  6. Barrat FJ, Coffman RL. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol. Rev. 2008;223:271–283
  7. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 2005;202:1131–1139
  8. Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 2007;37:3582–3586
  9. Bartfai T, Behrens S, Gaidarova S, Pemberton J, Shivanyuk A, Rebek J. A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses. Proc. Natl. Acad. Sci. U.S.A. 2003;100:7971–7976
  10. Barton GM, Kagan JC, Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat. Immunol. 2006;7:49–56
  11. Bayas A, Stasiolek M, Kruse N, Toyka KV, Selmaj K, Gold R. Altered innate immune response of plasmacytoid dendritic cells in multiple sclerosis. Clin. Exp. Immunol. 2009;157:332–342
  12. Bennett-Guerrero E, Grocott HP, Levy JH, Stierer KA, Hogue CW, Cheung AT, et al. A Phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (EE5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass. Anesth. Analg. 2007;104:378–383
  13. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 2007;8:57–69
  14. Broadley SA, Vanags D, Williams B, Johnson B, Feeney D, Griffiths L, et al. Results of a Phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in multiple sclerosis. Mult. Scler. 2009;15:329–336
  15. Bsibsi M, Bajramovic JJ, Vogt MH, van Duijvenvoorden E, Baghat A, Persoon-Deen C, et al. The microtubule regulator stathmin is an endogenous protein agonist for TLR3. J. Immunol. 2010;184:6929–6937
  16. Carpenter S, O'Neill LA. Recent insights into the structure of Toll-like receptors and post-translational modifications of their associated signalling proteins. Biochem. J. 2009;422:1–10(Review)
  17. Caso JR, Pradillo JM, Hurtado O, Lorenzo P, Moro MA, Lizasoain I. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation. 2007;115:1599–1608
  18. Chang YC, Kao WC, Wang WY, Yang RB, Peck K. Identification and characterization of oligonucleotides that inhibit Toll-like receptor 2-associated immune responses. FASEB. 2009;23:3078–3088
  19. Chearwae W, Bright JJ. 15-deoxy-Delta(12,14)-prostaglandin J(2) and curcumin modulate the expression of Toll-like receptors 4 and 9 in autoimmune T lymphocyte. J. Clin. Immunol. 2008;28:558–570
  20. Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, Wang JM. Toll-like receptors in inflammation, infection and cancer. Int. Immunopharmacol. 2007;7:1271–1285
  21. Chi H, Flavell RA. Innate recognition of non-self nucleic acids. Genome Biol. 2008;9:211.1–211.6
  22. Christ WJ, Asano O, Robidoux AL, Perez M, Wang Y, Dubuc GR, et al. E5531, a pure endotoxin antagonist of high potency. Science. 1995;268:80–83
  23. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity. 2006;25:417–428
  24. Correale G, Farez M. Helminth antigens modulate immune responses in cells from multiple sclerosis patients through TLR2-dependent mechanisms. J. Immunol. 2009;183:5999–6012
  25. Dillon S, Agrawal S, Banerjee K, Letterio J, Denning TL, Oswald-Richter K, et al. Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J. Clin. Invest. 2006;116:916–928
  26. Dorner M, Brandt S, Tinguely M, Zucol F, Bourquin JP, Zauner L, et al. Plasma cell Toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. Immunology. 2009;128:573–579
  27. Downer EJ, Clifford E, Gran B, Nel HJ, Fallon PG, Moynagh PN. Identification of the synthetic cannabinoid R(+)WIN55,212-2 as a novel regulator of IFN regulatory factor 3 activation and IFN-beta expression: relevance to therapeutic effects in models of multiple sclerosis. J. Biol. Chem. 2011;286:10316–10328
  28. Drexler SK, Foxwell BM. The role of Toll-like receptors in chronic inflammation. Int. J. Biochem. Cell Biol. 2010;42:506–518
  29. Dunn-Siegrist I, Leger O, Daubeuf B, Poitevin Y, Dépis F, Herren S, et al. Pivotal involvement of Fcgamma receptor IIA in the neutralization of lipopolysaccharide signaling via a potent novel anti-TLR4 monoclonal antibody 15C1. J. Biol. Chem. 2007;282:34817–34827
  30. Duramad O, Fearon KL, Chang B, Chang JH, Gregorio J, Coffman RJ, et al. Inhibitors of TLR9 act on multiple cell subsets in mouse and man “in vitro” and prevent death “in vivo” from systemic inflammation. J. Immunol. 2005;174:5193–5200
  31. Eitan O, Kathleen JG, Justin DL, Sung-Chun T, Thiruma VA. Toll-like receptors in neurodegeneration. Brain Res. Rev. 2009;59:278–292
  32. Fort MM, Mozaffarian A, Stoäver AG, Correia Jda S, Johnson DA, Crane RT, et al. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J. Immunol. 2005;174:6416–6423
  33. Galdiero M, Galdiero M, Finamore E, Rossano F, Gambuzza M, Catania MR, et al. Haemophilus influenzae porin induces Toll-like receptor 2-mediated cytokine production in human monocytes and mouse macrophages. Infect. Immun. 2004;72:1204–1209
  34. Gandhi R, Laroni A, Weiner HL. Role of the innate immune system in the pathogenesis of multiple sclerosis. J. Neuroimmunol. 2010;221:7–14
  35. Gay NJ, Keith FJ. Drosophila Toll and IL-1 receptor. Nature. 1991;351:355–356
  36. Glezer I, Chernomoretz A, David S, Plante MM, Rivest S. Genes involved in the balance between neuronal survival and death during inflammation. PloS One. 2007;21:2–e310
  37. Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors: emerging therapeutics?. Nat. Rev. Drug. Discov. 2010;9:293–307
  38. Hodgkinson L. Digestive Disease Week 2010. Turning science into medicine–part 2. IDrugs. 2010;13:424–426
  39. Hua F, Ma J, Ha T, Xia Y, Kelley J, Williams DL, et al. Activation of Toll-like receptor 4 signaling contributes to hippocampal neuronal death following global cerebral ischemia/reperfusion. J Neuroimmunol. 2007;190:101–111
  40. Hultqvist M, Nandakumar KS, Björklund U, Holmdah R. The novel small molecule drug Rabeximod is effective in reducing disease severity of mouse model of autoimmune disorders. Ann. Rheum. Dis. 2009;68:130–135
  41. Hultqvist M, Nandakumar KS, Bjorklund U, Holmdahl R. Rabeximod reduces arthritis severity in mice by decreasing activation of inflammatory cells. Ann. Rheum. Dis. 2010;69:1527–1532
  42. Ishii KJ, Takeshita F, Gursel I, Gursel M, Conover J, Nussenzweig A, et al. Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation. J. Exp. Med. 2002;196:269–274
  43. Iwami K, Matsuguchi T, Masuda A, Kikuchi T, Musikacharoen T, Yoshikai Y. Cutting edge: naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccharide signaling. J. Immunol. 2000;165:662–668
  44. Iyer S, Kontoyiannis D, Chevrier D, Woo J, Mori N, Cornejo M, et al. Inhibition of tumor necrosis factor mRNA translation by a rationally designed immunomodulatory peptide. J. Biol. Chem. 2000;275:17051–17057
  45. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur. J. Immunol. 2001;31:3388–3393
  46. Jasani B, Navabi H, Adams M. Ampligen: a potential Toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine. 2009;27:3401–3404
  47. Johnson BJ, Le TT, Dobbin CA, Banovic T, Howard CB, Flores Fde M, et al. Heat shock protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production. J. Biol. Chem. 2005;280:4037–4047
  48. Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat. Immunol. 2008;9:361–368
  49. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 2007;13:552–559
  50. Kawai T, Akira S. Signaling to NF-kappa B by Toll-like receptors. Trends Mol. Med. 2007;13:460–469
  51. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010;11:373–384
  52. Keller JN, Hanni KB, Gabbita SP, Friebe V, Mattson MP, Kindy MS. Oxidized lipoproteins increase reactive oxygen species formation in microglia and astrocyte cell lines. Brain Res. 1999;830:10–15
  53. Kenny EF, O'Neill LA. Signaling adaptors used by Toll-like receptors: an update. Cytokine. 2008;43:342–349
  54. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008;452:543–545
  55. Lassmann H. Mechanisms of inflammation induced tissue injury in multiple sclerosis. J. Neurol. Sci. 2008;274:45–47Review
  56. Ledeboer A, Hutchinson MR, Watkins LR, Johnson KW. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert. Opin. Investig. Drugs. 2007;16:935–950
  57. Lee JS, Lee JY, Lee MY, Hwang DH, Youn HS. Acrolein with an alpha, beta-unsaturated carbonyl group inhibits LPS-induced homodimerization of Toll-like receptor 4. Mol. Cells. 2008;25:253–257
  58. Lehnardt S. Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. In: Glia. 58:2010;p. 253–263
  59. Lehnardt S, Massillon L, Follett P, Jensen FE, Ratan R, Rosenberg PA, et al. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc. Natl. Acad. Sci. U.S.A. 2003;100:8514–8519
  60. Li Y, Chu N, Hu A, Gran B, Rostami A, Zhang GX. Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia. Brain. 2007;130:490–501
  61. Loiarro M, Capolunghi F, Fantò N, Gallo G, Campo S, Arseni B, et al. Pivotal advance: inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J. Leuk. Biol. 2007;82:801–810
  62. Mancuso G, Midiri A, Biondo C, Beninati C, Gambuzza M, Macrì D, et al. Bacteroides fragilis-derived lipopolysaccharide produces cell activation and lethal toxicity via Toll-like receptor 4. Infect. Immun. 2005;73:5620–5627
  63. Mancuso G, Gambuzza M, Midiri A, Biondo C, Papasergi S, Akira S, et al. Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells. Nat. Immunol. 2009;10:587–594
  64. Marsh BJ, Stenzel-Poore MP. Toll-like receptors: novel pharmacological targets for the treatment of neurological diseases. Curr. Opin. Pharmacol. 2008;8:8–13
  65. Marta M. Toll-like receptors in multiple sclerosis mouse experimental models. Ann. N.Y. Acad. Sci. 2009;1173:458–462
  66. Marta M, Andersson A, Isaksson M, Kämpe O, Lobell A. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur. J. Immunol. 2008;38:565–575
  67. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 2007;8:913–919
  68. Meng G, Rutz M, Schiemann M, Metzger J, Grabiec A, Schwandner R, et al. Antagonistic antibody prevents Toll-like receptor 2-driven lethal shock-like syndromes. J. Clin. Invests. 2004;113:1473–1481
  69. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415:536–541
  70. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J. Biol. Chem. 2001;276:10229–10233
  71. Okun E, Griffioen KJ, Lathia JD, Tang SC, Mattson MP, Arumugam TV. Toll-like receptors in neurodegeneration. Brain Res. Rev. 2008;59:278–292
  72. Olson JK, Miller SD. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J. Immunol. 2004;173:3916–3924
  73. O'Neill LA. Targeting signal transduction as a strategy to treat inflammatory diseases. Nat. Rev. Drug Discov. 2006;5:549–563
  74. O'Neill LA, Bryant CE, Doyle SL. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol. Rev. 2009;61:177–197
  75. Pawar RD, Ramanjaneyulu A, Kulkarni OP, Lech M, Segerer S, Anders HJ. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J. Am. Soc. Nephrol. 2007;18:1721–1726
  76. Pedras-Vasconcelos J, Puig M, Verthelyi D. TLRs as therapeutic targets in CNS inflammation and infection. Front. Biosci. 2009;1:476–487
  77. Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm. 2010;2010, 672395
  78. Prinz M, Garbe F, Schmidt H, Mildner A, Gutcher I, Wolter K, et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J. Clin. Invest. 2006;116:456–464
  79. Pulendran B, Tang H, Manicassamy S. Programming dendritic cells to induce TH2 and tolerogenic responses. Nat. Immunol. 2010;11:647–655
  80. Racke MK, Drew PD. Toll-like receptors in multiple sclerosis. Curr. Top. Microbiol. Immunol. 2009;336:155–168
  81. Robinson RA, De Vita VT, Levy HB, Baron S, Hubbard SP, Levine AS. A Phase I–II trial of multiple-dose polyriboinosinic-polyribocytidylic acid in patients with leukemia or solid tumors. J. Natl. Cancer Inst. 1976;57:599–602
  82. Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc. Natl. Acad. Sci. U.S.A. 1998;95:588–593
  83. Sarnico I, Lanzillotta A, Benarese M, Alghisi M, Baiguera C, Battistin L, et al. NF-kappaB dimers in the regulation of neuronal survival. Int. Rev. Neurobiol. 2009;85:351–362
  84. Schmidt C. Immune system's Toll-like receptors have good opportunity for cancer treatment. J. Natl. Cancer Inst. 2006;98:574–575
  85. Simon BR, Line SR, Paludan SR. Innate recognition of intracellular pathogens: detection and activation of the first line of defense. APMIS. 2009;117:323–327
  86. Slack EC, Robinson MJ, Hernanz-Falcon P, Brown GD, Williams DL, Schweighoffer E, et al. Syk-dependent ERK activation regulates IL-2 and IL-10 production by DC stimulated with zymosan. Eur. J. Immunol. 2007;37:1600–1612
  87. Sloane JA, Blitz D, Margolin Z, Vartanian T. A clear and present danger: endogenous ligands of Toll-like receptors. Neuromolecular Med. 2010;12:149–163Review
  88. Sloane JA, Batt C, Ma Y, Harris ZM, Trapp B, Vartarian T. Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2. Proc. Natl. Acad. Sci. 2010;25:11555–11560
  89. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005;23:683–747
  90. Stein RC, Waterfield MD. PI3-kinase inhibition; a target for drug development?. Mol. Med. Today. 2000;6:347–357
  91. Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 2009;11:155–161
  92. Strayer DR, Carter WA, Brodsky I, Cheney P, Peterson D, Salvato P, et al. A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome. Clin. Infect. Dis. 1994;18:S88–S95
  93. Sullivan T, Atiee G, Bhagat L, Jiang W, Kandimalla E, Murphy J, et al. Safety and pharmacodynamics of IMO-3100, a novel Toll-like receptor antagonist for autoimmune and inflammatory diseases, in a rising single-dose phase I clinical trial. In: 6th Annual Meeting of the Oligonucleotide Therapeutic Society being Held in Dana Point, California, Oct 20–23. 2010;
  94. Sun S, Rao NL, Venable J, Thurmond R, Karlsson L. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm. Allergy Drug Targets. 2007;6:223–235
  95. Takashima K, Matsunaga N, Yoshimatsu M, Hazeki K, Kaisho T, Uekata M, et al. Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model. Br. J. Pharmacol. 2009;157:1250–1252
  96. Touil T, Fitzgerald D, Zhang GX, Rostami A, Gran B. Cutting edge: TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-β. J. Immunol. 2006;177:7505–7509
  97. Trieu A, Roberts TL, Dunn JA, Sweet MJ, Stacey KJ. DNA motifs suppressing TLR9 responses. Clin. Rev. Immunol. 2006;26:527–544
  98. Tseng PH, Matsuzawa A, Zhang W, Mino T, Vignali DAA, Karin M. Different modes of ubiquination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nat. Immunol. 2010;11:70–75
  99. Ungaro R, Fukata M, Hsu D, Hernandez Y, Breglio K, Chen A, et al. A novel Toll-like receptor 4 (TLR4) antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2009;296:G1167–G1179
  100. Urbonaviciute V, Fürnrohr BG, Meister S, Munoz L, Heyder P, De Marchis F, et al. Induction of inflammatory and immune responses by HMGB 1-nucleosome complexes implications for the pathogenesis of SLE. J. Exp. Med. 2008;205:3007–3018
  101. Vaishnaw AK, Gollob J, Gamba-Vitalo C, Hutabarat R, Sah D, Meyers R, et al. A status report on RNAi therapeutics. Silence. 2010;8:1–14
  102. van Eden W. XToll, a recombinant chaperonin 10 as an anti-inflammatory immunomodulator. Curr. Opin. Investig. Drugs. 2008;9:523–533(Review)
  103. Veldhoen W, Hocking RJ, Flavell RA, Stockinger B. Signals mediated by transforming growth factor-β initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat. Immunol. 2006;7:1151–1156
  104. Von Bernuth H, Picard C, Jin Z, Pankla R, Xiao H, Ku CL, et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science. 2008;321:691–696
  105. Waldner H, Collins M, Kuchroo VK. Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J. Clin. Invest. 2004;113:990–997
  106. Wang D, Bhagat L, Yu D, Zhu FG, Tang JX, Kandimalla ER, et al. Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9. J. Med. Chem. 2009;52:551–558
  107. Watters TM, Kenny EF, O'Neil lLA. Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins. Immunol. Cell Biol. 2007;85:411–419
  108. Weiner HL. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch. Neurol. 2004;61:1613–1615
  109. Weiner HL. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J. Neurol. 2008;255:3–11
  110. Wittebole X, Castanares-Zapatero D, Laterre PF. Toll-like receptor 4 modulation as a strategy to treat sepsis. Mediators Inflamm. 2010;568396:Review
  111. Yong VW, Marks S. The interplay between the immune and central nervous systems in neuronal injury. Neurology. 2010;74:S9–S16
  112. Yu L, Wang L, Chen S. Endogenous Toll-like receptor ligands and their biological significance. J. Cell Mol. Med. 2010;14:2592–2603
  113. Zhang X, Jin J, Tang Y, Speer D, Sujkowska D, Markovic-Plese S. IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. J. Immunol. 2009;182:3928–3936

PII: S0165-5728(11)00227-X

doi: 10.1016/j.jneuroim.2011.08.010

Journal of Neuroimmunology
Volume 239, Issue 1 , Pages 1-12 , 28 October 2011

Article Tools

* Image Usage & Resolution